Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC

Cell Reports(2025)10.1016/j.celrep.2025.115543Source: DataRank Database

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC is a research paper published in Cell Reports (2025). On theSindex it has a DataRank of 0. It has been cited 41 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access41 citations

Download PDF

Cite:

Linked data & code

cellosaurus pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 31.84)OA: goldTopics (49)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Yicheng Guo ORCID,Ian A. Mellis ORCID,Madeline Wu,Hiroshi Mohri ORCID,Carmen Gherasim ORCID

Live enrichment

PubMed:40202847 PMC:PMC12014523 OpenAlex:https://openalex.org/W4409253311

Columbia University

Grant: UR014016

Columbia University

Grant: K24 AI155230

Columbia University

Grant: K23 AI171263

Gates Foundation

Grant: INV019355

National Institutes of Health

Grant: 75N93021C00016

National Institutes of Health

Grant: 75N93021C00014

National Institutes of Health

Grant: 0258-A700-4609

National Institutes of Health

Grant: GR0010139-PO024016

NIAID NIH HHS

Grant: UM1 AI069470

NIAID NIH HHS

Grant: U01 AI069470

FWCI

31.84

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.celrep.2025.115543

publisherhttps://doi.org/10.1016/j.celrep.2025.115543

publisherhttps://api.elsevier.com/content/article/PII:S2211124725003146?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124725003146?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40202847

Fields of Study

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyAnimal Virus Infections StudiesSARS-CoV-2HumansAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, CoronavirusAntibodies, MonoclonalAngiotensin-Converting Enzyme 2COVID-19Neutralization TestsMutationAnimalsSARS-CoV-2 variants

MeSH Terms

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2AnimalsAntibodies, MonoclonalAntibodies, ViralHumansMutationNeutralization TestsAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

AntibodyVirologyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBiologyImmunologyMedicineGeneticsOutbreakInternal medicineDiseaseMonoclonal antibodiesSerum NeutralizationMrna VaccinesAntibody EvasionSars-cov-2Ace2 InhibitionCp: MicrobiologyCp: ImmunologyKp.3.1.1Jn.1 SubvariantsXec

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC

FAIR Checklist

Authors (11)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)